MedTrace Logo

A Phase I Study of Single and Multiple Doses of VG290131 in Healthy Subjects

NCT06081465 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2024-07-26

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability and PK profiles of orally administered VG290131 in healthy subjects. The main questions it aims to answer are:

1. The safety and tolerability of VG290131 when administered orally as a single dose and multiple doses in healthy subjects.
2. The pharmacokinetic (PK) profiles of VG290131 and the food effect on the PK profiles of VG290131 in healthy subjects.

Approximately 86 subjects will be enrolled in the study.

Conditions

  • Healthy Volunteers

Interventions

DRUG

VG290131

The study drug and matching placebo will be administered orally.

Sponsors & Collaborators

  • Tigermed Consulting Co., Ltd

    collaborator INDUSTRY

  • Zhejiang Vimgreen Pharmaceuticals, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-20
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06081465 on ClinicalTrials.gov